DHCNI — Diversified Healthcare Trust -

Summary of DHCNI Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Normalized FFO: $39 million, or $0.16 per share.
• Adjusted EBITDAre: $82 million.
• Consolidated NOI: Increased by 20.4% year-over-year to $84 million.
• Same-property NOI (SHOP segment): Increased 37.2% year-over-year to $52 million.
• Average Monthly Rate: Increased by 6.2%.
• Same-property occupancy: Improved by 160 basis points to 83.1%.
• Liquidity: Approximately $267 million, with net debt to EBITDA at 7.1x, improved from 8.7x year-over-year.
• G&A Expenses: Included $10 million in incentive management fees and $2.3 million in noncash share-based compensation.

2. Strategic Updates and Business Highlights

• Continued operational momentum in the SHOP segment due to strategic changes made over the past year.
• Transition of operators completed in late 2025 is expected to enhance profitability through regional oversight and best practices.
• New management agreements set to commence in January 2027 aim to align legacy operators with a more performance-based fee structure, expected to yield $2 million in annual cost savings.
• Plans to invest approximately $20 million in converting closed skilled nursing wings into high-demand living units, anticipating mid-teens returns.
• The Medical Office and Life Science portfolio showed stable occupancy at 95.8%, with healthy leasing activity.

3. Forward Guidance and Outlook

• Reaffirmed full-year guidance for total NOI of $307 million to $323 million, with SHOP NOI of $185 million to $195 million.
• Adjusted EBITDAre guidance remains at $300 million to $315 million, and normalized FFO at $0.56 to $0.62 per share.
• Anticipated occupancy growth of 200 basis points, with revenue growth projected at 6.6% and average monthly rate growth at 5.5%.
• Expectation of continued margin expansion and operational improvements as new operator agreements take effect.

4. Bad News, Challenges, or Points of Concern

• Average occupancy and corresponding revenue are tracking slightly below initial 2026 projections, attributed to timing issues in operator transitions rather than fundamental demand issues.
• Notable decline in rental revenue in the Medical Office and Life Science segment due to a $1 million bad debt charge and upcoming tenant vacancies.
• The company acknowledged potential seasonality impacts in Q3 related to utility costs, which may affect profitability.

5. Notable Q&A Insights

• Management clarified that the slower top-line growth in the SHOP segment is primarily due to transition-related delays rather than a lack of focus on occupancy growth.
• There is confidence in achieving higher RevPOR as occupancy increases, with ancillary revenue contributing positively.
• Future cost savings from new contracts are expected, but current guidance reflects a conservative approach to growth assumptions.
• Management indicated that the bad debt charge was unrelated to upcoming vacancies, suggesting it was an isolated incident.

Overall, DHCNI's Q2 2026 results reflect strong operational improvements, particularly in the SHOP segment, while acknowledging some challenges related to occupancy growth and revenue stability in other segments. The company remains optimistic about its strategic initiatives and long-term growth potential.